Company
Tiziana Life Sciences Ltd
NASDAQ:TLSA
Tiziana Life Sciences Ltd is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. The company’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date.
163 stories · page 2 of 2
Orla Mining stock climbs on production results plus more daily small cap movers
More and less costly gold production boosted shares of Orla Mining Ltd Friday plus other big percentage movers on news from the small and micro cap space
Tiziana to focus near-term on developing intranasal drug to treat CNS-based autoimmune diseases
“We aim to become a leading company pioneering intranasal therapies for CNS-based diseases and have sufficient capital to fund our programs until the first quarter of 2024,” said interim CEO Gabriele Cerrone
Tiziana finishes enrolling first patient cohort for expanded access program evaluating Foralumab in advanced stage multiple sclerosis
“This is the first time that non-active SPMS patients may receive a higher, 100 mcg dosing of intranasal foralumab versus the 50-mcg dosing previously studied,” said Gabriele Cerrone, the interim CEO of Tiziana
Tiziana Life Sciences starts enrollment of first patient cohort in program to evaluate foralumab in non-active Secondary Progressive Multiple Sclerosis patients
"In addition to this exciting news about starting this new treatment program in non-active SPMS, we are pleased to report that we are on track to conduct PET scans on our first two patients from our original study in the upcoming months," s
Tiziana Life Sciences plans to submit IND for phase 1 trial of intranasal foralumab in Alzheimer's disease patients by Q3 2023
"I am thrilled to see the company advancing foralumab into another promising central nervous system (CNS)-related therapeutic area with high unmet need," said Tiziana chairman and interim CEO Gabriele Cerrone
Tiziana Life Sciences presents intranasal foralumab at Preserving the Brain scientific conference in Italy
“Having the first patient to ever receive intranasal foralumab for secondary progressive multiple sclerosis interviewed at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance thi
Archive
NA Proactive news snapshot: Auxico Resources, Gratomic, Forte Minerals, Appia Rare Earths & Uranium, Tiidal Gaming Group, Royal Helium, TraceSafe UPDATE...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment
"Coupled with our PET imaging data demonstrating inhibition of microglial activation, I am truly excited and encouraged by the clinical benefits shown so far for the first two expanded access patients receiving intranasal foralumab for SPMS
Tiziana Life Sciences says Brigham and Women's Hospital gets grant to explore use of intranasal anti-CD3 mAb in ALS
"This prestigious research grant will be used to further study the role of intranasal anti-CD3 mAb in dampening the microglial activation which amplifies ALS disease progression," said Howard L Weiner, chairman of Tiziana's scientific advis
Tiziana Life Sciences says study using nasal anti-CD3 (Foralumab) presented at the Alzheimer's Association International Conference
The study was presented virtually at the AAIC by Dr Howard L. Weiner, co-director of the Ann Romney Center for Neurologic Diseases at the Brigham and Women's Hospital and chairman of Tiziana's Scientific Advisory Board on Sunday, July 31, 2
Tiziana Life Sciences appoints Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately
The company noted that Dr Davis has extensive experience in new drug application (NDA) and biologic license application (BLA), US Food & Drug Administration (FDA) approvals and device clearances
Tiziana Life Sciences reports positive results from second patient in multiple sclerosis study of foralumab
The patient showed improvements based on Positron Emission Tomography imaging analysis, a neurologic exam and a timed 25-foot walk test
Tiziana Life Sciences receives FDA go-ahead to enroll more multiple sclerosis patients in expanded access program for treatment with intranasal foralumab
"Treatment with intranasal foralumab is a novel physiological approach to stimulate the mucosal immune system to induce disease-modifying benefits in the [central nervous system] by dampening microglial inflammation,” said Howard Weiner, ch
Tiziana Life Sciences announces initiation of a Phase 1b clinical trial to evaluate orally administered enteric-coated capsules of foralumab in patients with mild-to-moderate Crohn's Disease
Dr Kunwar Shailubhai, chief executive officer and chief scientific officer of Tiziana, commented: "The 'Holy Grail' for biologics is the 'switch' from parenteral (IV, SC) to oral administration as it is the most economical, non-invasive, an
Tiziana Life Sciences: Analyst shares his feedback from key opinion leader call on Foralumab
Zak’s Small Cap Research analystJohn Vandermosten said: “Of the observations by the investigators most noteworthy was intranasal Foralumab’s effect on microglial activation as imaged by PET [positron emission tomography]"
Tiziana Life Sciences announces positive clinical data from a person with secondary progressive multiple sclerosis
Signs of efficacy were detected, while Tiziana’s Foralumab was well tolerated and there were no adverse effects in the six months of therapy, which will be continued
Tiziana Life Sciences given nod for second patient to undergo multiple sclerosis treatment
Clinical data from the first patient, having completed three of six months, revealed the treatment was well tolerated by the patient with a favourable clinical response
Tiziana Life Sciences' half-term report reveals it has made progress on all fronts
Financially, the group seems well set with £38.6mln in the bank as at 30 June
Tiziana Life Sciences races at US open after exclusive licensing agreement with Precision BioSciences
The pair are looking to use Tiziana’s foralumab monoclonal antibody to enhance the next generation of cancer treatments.
Tiziana Life Sciences inks exclusive licensing deal with US group Precision BioSciences that takes it into CAR-T therapy
The US firm is hoping to use foralumab, Tiziana’s clinical-stage fully-human monoclonal antibody, as a lymphodepletion or ‘tolerising’ agent to improve the long-term success of CAR-T in cancer treatment
Tiziana Life Sciences set for Nasdaq move
Through a new entity the company will list on Nasdaq and delist from London
Tiziana Life Sciences: Peer reviewed scientific article underscores the potential of monoclonal antibody nasal spray as a take-home Covid treatment
The update comes ahead of the imminent launch of a phase II, proof-of-concept study of Foralumab
Tiziana Life Sciences pulls the trigger on phase II Covid trial after appointing a contract research group
Foralumab will be given to hospitalised patients with severe coronavirus as part of the Brazil trial that will build on earlier work in mild-to-moderate cases
Tiziana Life Sciences appoints head of regulatory affairs
Dr Kevin Shutz has 19 years pharma industry experience
Tiziana Life Sciences seeks UK funding for 'take-home' nasal COVID-19 treatment
The nasally administered human antibody drug Foralumab has shown early promise
US Investment bank repeats 'buy' and US$8 price target on Tiziana Life Sciences after flurry of positive news
Earlier this week Zacks Small-Cap Research reiterated its US$7.50 valuation of the stock – more than triple the current US$2.40 share price
Zacks Small-Cap Research repeats its valuation on Tiziana Life Sciences as company starts nasally administered Foralumab trial for SPMS
Tiziana Life Sciences is advancing three candidates for a variety of indications in autoimmune disease, cancer and coronavirus (COVID-19)
Tiziana Life hails 'major accomplishment as nasally administered antibody shows potential to treat degenerative diseases such as MS
The latest data come from a phase I assessment of Foralumab, which is being developed for a range of diseases
Tiziana Life Sciences initiates trial using nasally administered monoclonal antibody to treat a person with secondary progressive multiple sclerosis
This is the first time a nasally administered antibody has been given to a patient with SPMS
Tiziana Life Sciences confident of advancing drug development pipeline
Various clinical and pre-clinical trials are coming up across its two main drug candidates
Tiziana Life Sciences seeks clinical partner in Asia to progress work on liver cancer treatment
The firm has signed an agreement with Takanawa Japan to identify a suitable partner
Tiziana Life Sciences says Accustem Sciences business will be spun out on Nasdaq
The American electronic market has become the natural home to ambitious, growing healthcare companies
Tiziana Life says breast cancer prognostic business Accustem Sciences to list on Nasdaq
Nasdaq is the most appropriate market given the nature of Accustem's business
Zacks Small-Cap Research initiates coverage on Tiziana Life Sciences, which it expects to advance foralumab into "multiple clinical trials" this year
Zacks has placed a valuation on Tiziana of US$7.50 per ADR share